WO2000065043A1 - Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire - Google Patents
Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire Download PDFInfo
- Publication number
- WO2000065043A1 WO2000065043A1 PCT/FR2000/001060 FR0001060W WO0065043A1 WO 2000065043 A1 WO2000065043 A1 WO 2000065043A1 FR 0001060 W FR0001060 W FR 0001060W WO 0065043 A1 WO0065043 A1 WO 0065043A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vegf
- fgf
- recombinant
- vector
- nucleic acid
- Prior art date
Links
- 239000002870 angiogenesis inducing agent Substances 0.000 title claims abstract description 25
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 20
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 20
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 20
- 241000701161 unidentified adenovirus Species 0.000 title claims description 54
- 230000002950 deficient Effects 0.000 title claims description 12
- 208000002815 pulmonary hypertension Diseases 0.000 title abstract description 4
- 239000013598 vector Substances 0.000 claims abstract description 46
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 29
- 102000009521 Vascular Endothelial Growth Factor B Human genes 0.000 claims description 27
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims description 27
- 239000013612 plasmid Substances 0.000 claims description 26
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 25
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 18
- 239000003102 growth factor Substances 0.000 claims description 15
- 210000002889 endothelial cell Anatomy 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 4
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 4
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims description 3
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 3
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 3
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 claims 1
- 230000014509 gene expression Effects 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 31
- 230000002685 pulmonary effect Effects 0.000 description 15
- 230000003612 virological effect Effects 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 206010021143 Hypoxia Diseases 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 13
- 238000012546 transfer Methods 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 230000037430 deletion Effects 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 10
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 238000010276 construction Methods 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 230000007954 hypoxia Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000004872 arterial blood pressure Effects 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 208000000924 Right ventricular hypertrophy Diseases 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000001146 hypoxic effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 102000009088 Angiopoietin-1 Human genes 0.000 description 4
- 108010048154 Angiopoietin-1 Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 4
- 101000742579 Homo sapiens Vascular endothelial growth factor B Proteins 0.000 description 4
- 108010082093 Placenta Growth Factor Proteins 0.000 description 4
- 102100035194 Placenta growth factor Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 4
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 4
- 108020005202 Viral DNA Proteins 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000003989 endothelium vascular Anatomy 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 102000058241 human VEGFB Human genes 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 210000005241 right ventricle Anatomy 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 101150081880 FGF1 gene Proteins 0.000 description 3
- 101000846416 Homo sapiens Fibroblast growth factor 1 Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 210000002565 arteriole Anatomy 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102000009840 Angiopoietins Human genes 0.000 description 2
- 108010009906 Angiopoietins Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000701533 Escherichia virus T4 Species 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 102100040681 Platelet-derived growth factor C Human genes 0.000 description 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 102000058223 human VEGFA Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 108010017992 platelet-derived growth factor C Proteins 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 241000701242 Adenoviridae Species 0.000 description 1
- 102000009075 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100038909 Caveolin-2 Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 101100120051 Homo sapiens FGF1 gene Proteins 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 101150032643 IVa2 gene Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010066327 Keratin-18 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000032028 Microvascular Rarefaction Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000055647 human CSF2RB Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000002979 macrophagic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Definitions
- the present invention relates to the use of a vector comprising a nucleic acid encoding an angiogenic factor for the prevention, improvement and / or treatment of pulmonary arterial hypertension. It also relates to particular pharmaceutical compositions allowing the local and effective administration of these vectors.
- Pulmonary arterial hypertension is a frequent pathology, fatal in its serious forms, currently untreated outside transplantation.
- pulmonary arterial resistances obstructing the ejection of the right ventricle and compromising cardiac output.
- Several functional and structural anomalies of the pulmonary vascular wall participate in the development of PAH including: hypertension of smooth muscle cells with medial and intimal hypertrophy, accumulation of extra cellular matrix, vascular rarefaction with reduction of peripheral capillary density.
- the invention provides for the first time an effective method for the treatment of pulmonary arterial hypertension. This method is based on the use of vectors comprising a nucleic acid coding for an angiogenic factor.
- VEGF vascular endothelium growth factor
- VEGF vascular endothelial growth factor
- the gene encoding VEGF is made up of 8 exons.
- Four forms of peptides are generated by alternative splicing. They respectively include 121,165, 189 and 206 amino acids in humans.
- VEGF In adults, VEGF is expressed in many normal tissues, particularly the heart and lungs. This expression is not necessarily associated with significant angiogenesis.
- the different forms of VEGF recognize two receptors with tyrosine kinase activity of the fms family: the Flt-1 receptor and the Flk-1 receptor.
- the Flt-1 receptor (VEGFR) -l is a high affinity receptor (10 pM).
- the KDR or flk-1 or (VEGFR) -2 receptor is a low affinity receptor (750 pM) which is responsible for the mitogenic effects of the peptide.
- One of the most remarkable aspects of the regulation of VEGF expression is its sensitivity to hypoxic conditions. Relatively short periods of hypoxia have been shown to stimulate expression of VEGF by cells in culture in vitro, including cardiomyocytes and smooth muscle cells. However, the role of this factor in the development or prevention of pulmonary arterial hypertension is not known.
- the family of vascular endothelium growth factors also includes other molecules which can be used in the present invention such as PIGF (Placenta Growth Factor), VEGF-B, VEGF-C, VEGF-D and VEGF-E .
- VEGF and VEGF-B are, within the family of vascular endothelium growth factors, the forms more particularly preferred in the context of the invention.
- VEGF-B is produced in many adult tissues, especially the heart, skeletal muscle and the pancreas. Two forms of peptides are generated by alternative splicing and include 167 and 186 amino acids, respectively.
- VEGF-B stimulates the proliferation of endothelial cells but it does not bind to the VEGFR-2 receptor.
- the fibroblast growth factor family includes many representatives and, to date, at least 14 members have been identified (for a review see Birnbaum et al. Medicine and Science 13, p 392 - 396, 1997). Although the forms of FGF-1 and FGF-2 are expressed in cells of the pulmonary epithelium and at the level of vascular cells in the lung, no information is available on the expression of these factors in relation to pulmonary hypertension, neither on the capacity of these factors to induce proliferation of endothelial cells and smooth muscle cells in the lung, nor on the expression of these factors in the bronchial or alveolar epithelial cells in relation to different environmental conditions and in particular the conditions of hypoxia.
- FGF-1 and FGF-2 are expressed in cells of the pulmonary epithelium and at the level of vascular cells in the lung, no information is available on the expression of these factors in relation to pulmonary hypertension, neither on the capacity of these factors to induce proliferation of endothelial cells and smooth muscle cells in the lung, nor on the expression of these factors in the bronchi
- angiogenic factors in the prevention and treatment of hypoxic pulmonary arterial hypertension
- the applicant used as a model rats in chronic hypoxia.
- the transfer of nucleic acids coding for angiogenic factors was carried out by means of recombinant vectors of the adenovirus type administered by intratracheal instillation.
- the results obtained show that the expression in the lung of angiogenic factors such as in particular VEGF-B or FGF-1 makes it possible to reduce the pulmonary arterial pressure, prevent right ventricular hypertrophy and pulmonary vascular remodeling.
- the invention thus provides, for the first time, an effective treatment method for pulmonary arterial hypertension.
- fibroblast growth factors members of the family of fibroblast growth factors (FGF), and more particularly FGF-1, FGF-2, FGF-4, and FGF-5, growth factors of the vascular endothelium and more particularly VEGF, VEGF-B, VEGF-C, VEGF-D, VEGF-D and PIGF (Placenta Growth Factor) and the factors angiopoietin type (angiopoietin 1 and angiopoietin 2).
- FGF fibroblast growth factors
- a first object of the invention relates to the use of a vector comprising a nucleic acid encoding an angiogenic factor for the preparation of a pharmaceutical composition intended for the prevention, the improvement and / or the treatment of hypertension pulmonary arterial.
- the angiogenic factor is a growth factor for endothelial cells chosen from the family of FGF or VEGF or angiopoietin, or a combination of at least two factors chosen from at least one of these families.
- the combination associating at least FGF-1 and VEGF the combination associating at least FGF-1 and VEGF-B, the combination associating at least FGF -1 and angiopoietin 1, the combination combining at least VEGF and angiopoietin 1 and the combination associating at least VEGF-B and angiopoietin 1.
- the growth factor of endothelial cells is chosen from FGF-1, FGF-2, FGF-4, FGF-5, or their variants.
- the endothelial cell growth factor is chosen from VEGF, VEGF-B, VEGF-C, VEGF-D, VEGF-E or their variants ⁇
- the endothelial cell growth factor is selected from VEGF or VEGF-B.
- the term "variant" of a polypeptide or protein is any analog, fragment, derivative or mutated form which is derived from a polypeptide or a protein and which retains at least one biological function. said polypeptide or said protein.
- Different variants of a polypeptide or protein can exist in their natural state. These variants can be allelic variations characterized by differences in the nucleotide sequence of the structural genes coding for the protein or can result from differential splicing or from post-translational modifications. These variants can be obtained by substitution, deletion, addition and / or modification of one or more amino acid residues. These modifications can be carried out by any techniques known to those skilled in the art.
- variants are in particular molecules having a greater affinity for their binding sites, sequences allowing improved expression in vivo, molecules exhibiting greater resistance to proteases, molecules having greater therapeutic efficacy or lesser side effects, or possibly new biological properties.
- FGF-1 there may be mentioned more particularly the natural variants of FGF-1, such as the forms described in US Pat. No. 4,868,1 13 and comprising 154 amino acids, 140 amino acids or 134 amino acids.
- VEGF there may be mentioned the forms VEGF 12 ,, VEGF, 6S , VEGF, 89 and VEGF 20 .
- VEGF-B mention may be made of the forms VEGF 186 and VEGF, 67 .
- variants which can be used in the context of the invention are in particular the molecules in which one or more residues have been substituted, the derivatives obtained by deletion of regions having little or no involvement in the interaction with the binding sites considered or expressing an undesirable activity, and the derivatives comprising, relative to the native sequence, additional residues, such as for example a secretion signal and / or a junction peptide.
- the nucleotide sequence coding for the angiogenic factor also contains a secretion signal making it possible to direct the FGF-1 synthesized in the secretory pathways of the infected cells, so that the FGF - 1 synthesized is released more efficiently in the extracellular compartments and can activate its receptors.
- the secretion signal used can be a heterologous or even artificial secretion signal.
- the DNA sequence coding for the angiogenic factor used in the context of the present invention may be a cDNA, a genomic DNA (gDNA), or a hybrid construct consisting, for example, of a cDNA in which one or more introns would be inserted. They can also be synthetic or semi-synthetic sequences. Particularly advantageously, a cDNA or a gDNA is used. In particular, the use of a gDNA can allow better expression in human cells.
- the sequence coding for the angiogenic factor is placed under the control of signals allowing its expression in the cells of the pulmonary epithelium.
- these are heterologous expression signals, that is to say signals different from those naturally responsible for the expression of the angiogenic factor.
- They may in particular be sequences responsible for the expression of other proteins, or synthetic sequences.
- they may be promoter sequences of eukaryotic or viral genes.
- they may be promoter sequences originating from the genome of the cell which it is desired to infect.
- they may be promoter sequences derived from the genome- of a virus, including the adenovirus used.
- these expression sequences can be modified by adding activation, regulation sequences or allowing tissue-specific expression. It may indeed be particularly advantageous to use expression signals which are active specifically or predominantly in the cells of the pulmonary epithelium, so that the DNA sequence is not expressed and does not produce its effect until the vector actually infected these cells; in this regard, there may be mentioned, for example, the promoter of the cytokeratin 18 gene.
- the nucleic acid encoding one or more angiogenic factors is introduced into a vector.
- the term "vector” means any means allowing the transfer of a nucleic acid into a host cell, preferably at the level of the lung and more particularly at the level of the pulmonary epithelium.
- the term vector includes viral and non-viral vectors for the transfer of a nucleic acid into a cell in vivo or ex vivo.
- a type of vector for implementing the invention can be, for example, a plasmid, a cosmid or any DNA not encapsulated by a virus, a phage, an artificial chromosome, a recombinant virus, etc. It is preferably a plasmid or a recombinant virus.
- plasmid type vectors mention may be made of all the cloning and / or expression plasmids known to those skilled in the art and which generally have an origin of replication. Mention may also be made of plasmids carrying origins of replication and / or improved selection markers as described for example in applications WO96 / 26270 and WO97 / 10343.
- adenovirus viruses adenovirus viruses
- retroviruses hehes virus
- lentiviruses recombinant adeno-associated viruses or SV40 virus.
- the construction of this type of recombinant virus defective for replication has been widely described in the literature, as well as the infection properties of these vectors (see in particular S. Baeck and K-.L March (1998), Circul. Research vol. 82, pp 295-305), T. Shenk, BN Fields, DM Knipe, PM Howley et al (1996), Adenoviridae: the viruses and their replication (in virology).
- Pp 211-2148 EDS - Ravenspublishers / Philadelphia, P. Yeh and M. Perricaudet (1997), FASEB Vol. 11, pp 615-623.
- a particularly preferred recombinant virus for the implementation of the invention is a defective recombinant adenovirus.
- Adenoviruses are linear double-stranded DNA viruses around 36 (kilobases) kb in size. There are different serotypes, the structure and properties of which vary somewhat, but which have a comparable genetic organization. More particularly, the recombinant adenoviruses can be of human or animal origin. As regards adenoviruses of human origin, mention may preferably be made of those classified in group C, in particular adenoviruses of type 2 (Ad2), 5 (Ad5), 7 (Ad7) or 12 (Ad 12).
- adenoviruses of animal origin mention may preferably be made of adenoviruses of canine origin, and in particular all the strains of the adenovirus CAV2 [manhattan or A26 / 61 strain (ATCC VR-800) for example].
- Other adenoviruses of animal origin are cited in particular in application WO94 / 26914 incorporated herein by reference.
- the adenovirus genome includes in particular a repeated inverted sequence (ITR) at each end, an encapsidation sequence (Psi), early genes and late genes.
- ITR inverted sequence
- Psi encapsidation sequence
- the main early genes are contained in the E1, E2, E3 and E4 regions. Among these, the genes contained in the El region in particular are necessary for viral propagation.
- the main late genes are contained in regions L1 to L5.
- the genome of the Ad5 adenovirus has been fully sequenced and is accessible on the database (see in particular Genbank M73260). Likewise, parts or even all of other adenoviral genomes (Ad2, Ad7, Ad 12, etc.) have also been sequenced.
- adenovirus For their use as recombinant vectors, various constructs derived from adenoviruses have been prepared, incorporating different therapeutic genes. In each of these constructions, the adenovirus was modified so as to render it incapable of replication in the infected cell. Thus, the constructions described in the prior art are deleted adenoviruses from the E1 region, essential for viral replication, at the level of which heterologous DNA sequences are inserted (Levrero et al., Gene 101 (1991) 195; Gosh-Choudhury et al., Gene 50 (1986) 161). Furthermore, to improve the properties of the vector, it has been proposed to create other deletions or modifications in the genome of the adenovirus.
- thermosensitive point mutation was introduced in the mutant ts125, making it possible to inactivate the DNA binding protein of 72kDa (DBP) (Van der Vliet et al., J. Virol., 1975, 15 (2) 348-354).
- DBP 72kDa
- Other vectors include a deletion of another region essential for viral replication and / or spread, the E4 region.
- the E4 region is in fact involved in the regulation of the expression of late genes, in the stability of late nuclear RNA, in the extinction of the expression of proteins of the host cell and in the efficiency of replication of l 'Viral DNA.
- Adenoviral vectors in which the E1 and E4 regions are deleted therefore have very reduced transcription background noise and expression of viral genes.
- the recombinant adenovirus is a human adenovirus of group C. More preferably, it is an adenovirus Ad2 or Ad5.
- the recombinant adenovirus used in the context of the invention comprises a deletion in the E1 region of its genome. Even more particularly, it includes a deletion of the Ela and Elb regions. By way of example, mention may be made of deletions affecting nucleotides 454-3328; 386-3446 or 357-4020 (with reference to the Ad5 genome).
- the recombinant adenovirus used in the context of the invention further comprises a deletion in the E4 region of its genome. More particularly, the deletion in the E4 region affects all of the open phases. As a specific example, the deletions 33466-35535 or 33093-35535 can be cited. Other types of deletions in the E4 region are described in applications WO95 / 02697 and WO96 / 22378, which are incorporated herein by reference.
- the expression cassette containing the nucleic acid coding for an angiogenic factor can be inserted at different sites of the recombinant genome. It can be inserted at the level of the E1, E3 or E4 region, replacing the deleted or su séquenceslus sequences. It can also be inserted at any other site, apart from the sequences necessary in cis for the production of viruses (ITR sequences and packaging sequence).
- the term "expression cassette" of a nucleic acid means a DNA fragment which can be inserted into a vector at specific restriction sites; the DNA fragment comprises, in addition to the nucleotide sequence coding for an RNA or a polypeptide of interest, the sequences necessary for the expression (enhancer (s), promoter (s), polyadenylation sequence, etc.) of said sequence of interest.
- the DNA fragment and the restriction sites are designed to ensure insertion of said fragment into a reading frame suitable for transcription and / or translation.
- Recombinant adenoviruses are produced in an packaging line, that is to say a cell line capable of complementing in trans one or more of the deficient functions in the recombinant adenoviral genome.
- packaging lines known to those skilled in the art, mention may be made, for example, of line 293 in which a part of the adenovirus genome has been integrated.
- line 293 is a human embryonic kidney cell line containing the left end (approximately 1 1-12%) of the genome of the adenovirus serotype 5 (Ad5), comprising the left ITR, the region of encapsidation, the El region, including Ela and Elb, the region coding for the protein pIX and part of the region coding for the protein pIVa2.
- This line is capable of trans-complementing recombinant adenoviruses defective for the E1 region, that is to say devoid of all or part of the E1 region, and to produce viral stocks having high titers.
- This line is also capable of producing, at permissive temperature (32 ° C.), stocks of virus further comprising the thermosensitive E2 mutation.
- Other cell lines capable of complementing the E1 region have been described, based in particular on human lung carcinoma cells A549 (WO94 / 28152) or on human retinoblasts (Hum. Gen. Ther. (1996) 215).
- lines capable of trans-complementing several functions of the adenovirus have also been described. In particular, mention may be made of lines complementing the El and E4 regions (Yeh et al., J. Virol. Vol. 70 (1996) pp 559-565; Cancer Gen. Ther. 2 (1995) 322; Krougliak et al. , Hum. Gen. Ther. 6 (1995) 1575) and lines complementing the El and E2 regions (WO94 / 28152, WO95 / 02697, WO95 / 27071).
- Recombinant adenoviruses are usually produced by the introduction of viral DNA into the packaging line, followed by lysis of the cells after approximately 2 or 3 days (the kinetics of the adenoviral cycle being 24 to 36 hours).
- the viral DNA introduced may be the complete recombinant viral genome, optionally constructed in a bacterium (WO96 / 25506) or in a yeast (WO95 / 03400), transfected in the cells. It can also be a recombinant virus used to infect the packaging line.
- the viral DNA can also be introduced in the form of fragments each carrying a part of the recombinant viral genome and a zone of homology making it possible, after introduction into the packaging cell, to reconstitute the recombinant viral genome by homologous recombination between the different fragments .
- the recombinant viral particles are isolated by centrifugation in a cesium chloride gradient.
- An alternative method has been described in application WO98 / 00528 which is inconsistent with the present by reference.
- a vector suitable for implementing the present invention mention may in particular be made of: the recombinant adenovirus comprising the gene coding for human FGF-1 or human VEGF-B as described in the present invention, or the recombinant adenovirus comprising the gene coding for the isoform 165 of human VEGF as described in M ⁇ lhauser J et al (VEGF 165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Wax Res. 195; 77: 1077 -1086) inco ⁇ orated by reference to this.
- the invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising a vector as described above and a physiologically acceptable vehicle.
- the pharmaceutical compositions of the invention can be formulated for oral, parenteral, intranasal, intraarterial, intravenous, etc. administration.
- the pharmaceutical composition contains pharmaceutically acceptable vehicles for a formulation intended to be administered by the intratracheal route, in particular by instillation, or by the intravenous route.
- pharmaceutically acceptable vehicles for a formulation intended to be administered by the intratracheal route in particular by instillation, or by the intravenous route.
- They can be in particular saline solutions (monosodium phosphate, disodium, sodium chloride, potassium, calcium or magnesium, etc., or mixtures of such salts), sterile, isotonic, or dry compositions, in particular lyophilized, which, by addition, as the case may be, of sterilized water or physiological saline, allow the constitution of solutes intended for intratracheal instillation.
- the doses used for instillation or injections can be adapted as a function of various parameters, and in particular as a function of the mode of administration used, of the gene to be expressed, or also of the duration of the expression sought.
- the recombinant viruses according to the invention are formulated and administered in the form of doses of between 10 ⁇ and 10 ⁇ pf u, preferably 10 "to 101" pfu.
- the term pfu (“plaque forming unit”) corresponds to the infectious power of a viral solution, and is determined by infection of an appropriate cell culture, and measurement of the number of plaques of infected cells. The Techniques for determining the pfu titer of a viral solution are well documented in the literature.
- compositions according to the invention can also comprise a chemical or biochemical transfer agent.
- chemical or biochemical transfer agent is understood to mean any compound (i.e., other than a recombinant virus) facilitating the penetration of a nucleic acid into a cell. They can be cationic non-viral agents such as cationic lipids, peptides, polymers (Polyethylene Imine, Polylysine), nanoparticles; or non-cationic non-viral agents such as non-cationic liposomes, polymers or non-cationic nanoparticles.
- compositions according to the invention comprise a defective recombinant vector comprising a gene coding for a growth factor of endothelial cells and are formulated for intratracheal administration.
- compositions of the invention comprise from 10 4 to 10 14 pfu, and preferably from 10 6 to 10 10 pfu.
- a subject of the invention is also a process for preparing a medicament useful for the prevention, improvement and / or treatment of pulmonary arterial hypertension, characterized in that a recombinant vector comprising a coding nucleic acid is mixed for a growth factor with one or more compatible and pharmaceutically acceptable adjuvants.
- the invention also relates to a method of treating a mammal, and in particular a man, exhibiting pulmonary arterial hypertension comprising the administration of an effective amount of a recombinant vector comprising a nucleic acid coding for a growth factor. endothelial cells.
- Figure 1 obtaining the plasmid pXL3264 generated by double recombination from the plasmids pXL3208 and pXL3215 according to the method described by Crouzet et al
- Plasmid pXL3264 contains the genome of a type 5 adenovirus deleted for the E1 and E3 region and contains the expression cassette CMV-spFGF1-SV40.
- FIG. 2 representation of the vector pXL3179.
- the plasmid pXL3179 is a vector derived from the plasmid pXL2774 (WO97 / 10343) in which the gene coding for a fusion between the signal peptide of human fibroblast interferon and the cDNA of FGFl (Fibroblast Growth Factorl) (sp-FGFl, Jouanneau et al., 1991 PNAS 88: 2893-2897) was introduced under the control of the promoter from the early region of the human cytomegalovirus (hCMV IE) and the polyadenylation signal from the late region of the SV40 virus (Genbank SV4CG) .
- FGFl Fibroblast Growth Factorl
- Figure 3 representation of the vector pXL3636 and pXL3637. These vectors have a structure comparable to the plasmid pXL3208 and respectively comprise a sequence coding for VEGF-B, 67 (pXL3636) and VEGF-B, 86 (pXL3637) in place of sp-FGF-1 (pXL3208, FIG. 1).
- the DNA fragments can be separated according to their size by electrophoresis in agarose or acrylamide gels, extracted with phenol or with a phenol / chloroform mixture, precipitated with ethanol and then incubated in the presence of the DNA ligase from phage T4 (Biolabs) according to the supplier's recommendations.
- the filling of the protruding 5 ′ ends can be carried out by the Klenow fragment of DNA Polymerase I of E. coli (Biolabs) according to the supplier's specifications.
- the destruction of the protruding 3 ′ ends is carried out in the presence of the DNA polymerase of phage T4 (Biolabs) used according to the manufacturer's recommendations.
- the destruction of the protruding 5 ′ ends is carried out by a gentle treatment with nuclease S 1.
- Mutagenesis directed in vitro by synthetic oligodeoxynucleotides can be carried out according to the method developed by Taylor et al. [Nucleic Acids Res. L3_ (1985) 8749-8764] using the kit distributed by Amersham.
- Verification of the nucleotide sequences can be carried out by the method developed by Sanger et al. [Proc. Natl. Acad. Sci. USA, 74 (1977) 5463-5477] using the kit distributed by Amersham.
- Example 1 Construction of recombinant adenoviruses expressing the FGF-1 protein.
- This example describes the construction of an adenoviral vector carrying the gene coding for the protein FGF-1 operably linked to the CMN promoter.
- the human AD ⁇ c coding for human FGF-1 comprises 490 base pairs and codes for a polypeptide of 154 amino acids also called ECGF ⁇ for bet ⁇ -endothelial cell growth factor.
- ECGF ⁇ for bet ⁇ -endothelial cell growth factor.
- FGF-1 sp-FGF-1
- sp-FGF-1 present in the adenovirus described below is in fact a fusion protein between FGF-1 (aa 21-154) and a signal peptide of human interferon bet ⁇ described by Jouanneau et al (P. ⁇ .AS (1991) 88: 2893-2897).
- sp-FGF-1 is under the control of the cytomegalovirus enhancer / promoter (CMV, nucleotides -522 to +72) (Boshart et al. 1985, Cell, 41: 521-530).
- CMV cytomegalovirus enhancer / promoter
- the polyadenylation site of the SV40 virus is inserted late 3 ′ of the AD ⁇ c of sp-FGF-1.
- the assembly formed by (i) the enhancer / promoter of the cytomegalovirus, (ii) the AD ⁇ c of sp-FGF-1 and (iii), the polyadenylation site of the SV40 virus is hereinafter called the expression cassette of FGF- 1.
- the adenovirus was constructed according to the method described by Crouzet et al (P ⁇ AS vol 94 p 1414, 1997) by homologous recombination between the plasmid pXL3208 and the plasmid pXL3215.
- the plasmid pXL3215 contains the genome of an adenovirus containing an RSV-LacZ cassette inserted in its E1 region. The principle of the construction is described in FIG. 1.
- the plasmid pXL3264 generated by this double recombination contains the genome of an adenovirus of type 5 deleted for region E 1 and E3 and containing the CMV-spFGFl-SV40 expression cassette. This construction is verified by sequencing the FGF-1 expression cassette.
- the adenovirus AV1.0 CMV-FGF1 is generated by transfection of the DNA of pXL3264 digested with Pacl in line 293 (ATCC CRL-1573). The viral particles obtained are then amplified in this same line and stocks of viruses produced by double gradient of CsCl.
- the viral particles are then used to study the expression of the human spFGF1 gene in C2C12 cells, mouse myoblastic cells (ATCC CRL-1772) or W162 cells (Weinberg DH and Ketner GA 1983, PNAS 80: 5383 - 5386) .
- a Northern-blot is performed on W162 cells after infection with
- Plasmid pXL3179 is shown in Figure 2.
- a Western blot was performed on C2C12 cells after infection with MOIs from 30 to 3000 and harvesting of supernatants after 48 h.
- the FGFl is revealed by an antico ⁇ s anti-FGFl polyclonal of purified rabbit followed by an antico ⁇ s anti goat rabbit conjugated with peroxidase.
- the peroxidase activity is then revealed by chemiluminescence (ECL, Amersham) and detected on a Lumi-Imager (Roche diagnostics).
- the culture supernatant of C2C12 cells is used to verify that the expressed form of FGF is biologically active.
- Serial dilutions 1/200 and
- This example describes the construction of an adenoviral vector carrying the gene coding for the protein VEGF-B operably linked to the CMV promoter.
- VEGF-B vascular endothelial growth factor-B 167 and VEFG-B 186 , the corresponding nucleotide sequences of which are available under the references HSU48801 (VEGF-B I67 ) and HSU43368 (VEFG-B 186 ) in GenBank.
- adenoviruses AVI .0-CMV-VEGF-B 167 and AVI .0-CMV- VEFG-B 186 were constructed in a similar manner to the vector AVI.0-CMV-spFGF-1 from the vectors pXL3636 and pXL3637 (FIG. 3 ).
- the expression of VEGF-B 167 or VEFG-B I86 is placed under the control of the enhancer / promoter of the cytomegalovirus (CMV, nucleotides -522 to +72) (Boshart et al. 1985, Cell, 41: 521 - 530).
- the polyadenylation site of the SV40 virus (nucleotides 2538 to 2759 from the SV40 genome, Genbank locus SV4CG) is inserted 3 'to the VEGF-B 167 or VEFG-B l86 cDNA
- the adenovirus was constructed according to the method described by Crouzet et al (PNAS vol 94 pl414, 1997) by homologous recombination between the plasmid pXL3636 (VEGF-B 167 ) and the plasmid pXL3215 or the plasmid pXL3637 (VEFG-B, 86 ) and the plasmid pXL3215.
- the plasmid pXL3215 contains the genome of an adenovirus containing an RSV-LacZ cassette inserted in its E1 region. The principle of the construction is described in FIG. 1.
- the plasmid generated by this double recombination contains the genome of a type 5 adenovirus deleted for the E1 and E3 region and containing either the cassette CMV-VEGF-B 167 - S V40 expression cell, or the CMV-VEGF-B 186 -SV40 expression cassette.
- the adenoviruses AV1.0-CMN-NEGF-B 167 and AV1.0-CMV-VEFG-B I86 are generated by transfection of the plasmids generated by the double recombination digested by Pacl in line 293 (ATCC CRL-1573).
- the viral particles obtained are then amplified in this same line and stocks of viruses produced by double gradient of CsCl.
- Example 3 Intrapulmonary transfer of AV 1.0 CMV-FGF1 in rats.
- This example describes the transfer of the gene coding for human FGF-1 in the rat with the vector AV1.0 CMV-FGF1 described above.
- An identical recombinant adenovirus but not containing the FGF-1 expression cassette (AV 1.0 CMV. ⁇ ull) was used in the control animals.
- One month old male Wistar rats (200-250 g) are randomly divided into two groups. After anesthesia by intraperitoneal injection of a mixture of Ketamine (100 mg / kg) and Xylasine (2 mg / kg), they receive either the vector AV1.0 CMV-FGF1 or the control vector AV1.0 CMV. ⁇ ull in intratracheal instillation at a dose of 10 8 pfu (diluted in PBS for a final volume of 150 ⁇ l). This dose was chosen after a dose-response study comprising an ELISA assay of the protein FGF-1 in the bronchoalveolar lavage fluid and in the serum of the animals. 48 hours after the administration of the virus, the animals are exposed to a hypoxic gas mixture (Fio2 10%) under normobaric conditions (Flufrance cabinet, Cachan, France) for a period of 15 days.
- a hypoxic gas mixture (Fio2 10%) under normobaric conditions (Flufrance cabinet, Cachan,
- Example 4 Intrapulmonary transfer of AV1.0-CMV-VEGF-B 167 and AV1.0-CMN-NEFG-B 186 in rats. Intrapulmonary transfer of AN1.0-CMN-NEGF-B 167 and AV1.0-CMV-NEFG-B, 86 in rats was carried out under conditions identical to those described in Example 3. A recombinant adenovirus containing not the NEGF-B expression cassette (AV 1.0 CMV. ⁇ ull) was used in the control animals.
- Example 5 Evaluation of the efficiency of the intrapulmonary transfer of the gene coding for human VEGF-B in the rat.
- the evaluation takes place after 15 days of exposure to hypoxia according to the criteria listed below.
- the ELISA assay of the human VEGF-B protein is carried out in the serum and the broncoalveolar liquid (LBA) of the animals after 15 days of exposure to hypoxia.
- the factor VEGF-B is not found in the serum of any of the control animals whatever the conditions applied (e. With or without hypoxia).
- the concentration of VEGF-B is zero in the LBA of animals treated with defective recombinant adenovirus vectors encoding VEGF-B (form 167 or form 186).
- PAH PAH pulmonary arterial pressure
- Rats treated with AV1.0 CMVNEGF-B 167 or AV1.0 CMV-VEGF, 86 have significantly lower pulmonary blood pressure than rats given AdCMV. ⁇ ull, while systemic blood pressure and heart rate do not are not significantly different between the two groups (treated and control).
- Right ventricular hypertrophy is evaluated by the ratio of the weight of the right ventricle to the weight of the left ventricle + septum.
- the histological study of the lungs shows that at a dose of 10 8 pfu, the inflammatory lesions are very limited: absence of edema and hemorrhage, absence of lesions of the bronchial or alveolar epithelia. It is often observed a macrophagic interstitial granuloma, regardless of the treatment administered.
- the histomo ⁇ hometric study of the lungs is carried out according to two criteria (i) the study of the thickness of the arterial wall (arterioles of diameter ⁇ 200 ⁇ m) normalized to the size of the artery and (ii), the study of percentage non-muscularized, partially muscularized or completely muscularized arteries at the alveolar and alveolar canal level.
- the thickness of the arterial wall is determined and the results obtained show that the thickness of the arterial wall normalized to the size of the artery is significantly smaller in the rats having received the vector AV 1.0 CMVNEGF- B than in those treated by AV1.0 CMV. ⁇ ull.
- the percentage of non-muscularized, partially muscularized or completely muscularized arteries at the alveolar and alveolar canal level has been determined and the results obtained show that the percentage of non muscularized arteries both at the alveolar level and at the level of the alveolar canal. in rats treated with defective recombinant adenovirus vectors encoding VEGF-B.
- Example 6 Evaluation of the efficiency of the intrapulmonary transfer of the human FGF-1 gene in the rat.
- the evaluation takes place after 15 days of exposure to hypoxia according to the criteria listed below.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA01010849A MXPA01010849A (es) | 1999-04-26 | 2000-04-21 | Utilizacion de adenovirus recombinante defectuoso que comprende un acido nucleico que codifica para un factor angiogenico para el tratamiento de la hipertension arterial pulmonar. |
EP00922713A EP1173564A1 (fr) | 1999-04-26 | 2000-04-21 | Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire |
BR0010034-0A BR0010034A (pt) | 1999-04-26 | 2000-04-21 | Utilização de um vetor, processo de preparação de um medicamento útil para a prevenção, a melhoria e/ou o tratamento da hipertensão arterial pulmonar, e, composição farmacêutica |
CA002370404A CA2370404A1 (fr) | 1999-04-26 | 2000-04-21 | Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire |
SI200020023A SI20750A (sl) | 1999-04-26 | 2000-04-21 | Uporaba defektnega rekombinantnega virusa, ki vsebuje nukleinsko kislino, ki kodira za angiogenski faktor, za zdravljenje pljučne arterijske hipertenzije |
NZ515233A NZ515233A (en) | 1999-04-26 | 2000-04-21 | Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension |
JP2000614380A JP2002543097A (ja) | 1999-04-26 | 2000-04-21 | 肺動脈高血圧を治療するための血管新生促進因子をコードする核酸を含む組換え欠陥アデノウイルスの使用 |
IL14583400A IL145834A0 (en) | 1999-04-26 | 2000-04-21 | Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension |
KR1020017013633A KR20020001846A (ko) | 1999-04-26 | 2000-04-21 | 폐순환승압을 치료하기 위한 맥관형성 인자를 암호화 하는핵산을 포함하는 재조합 결손 아데노바이러스의 용도 |
AU43017/00A AU782833B2 (en) | 1999-04-26 | 2000-04-21 | Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension |
NO20015223A NO20015223D0 (no) | 1999-04-26 | 2001-10-25 | Anvendelse av defektive rekombinante adenovirus inneholdende en nukleinsyre som koder for en angiogenisk faktor for behandlingav pulmon¶r arteriell hypertensjon |
US09/983,885 US20020086004A1 (en) | 1999-04-26 | 2001-10-26 | Use of a defective recombinant adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9905272A FR2792531B1 (fr) | 1999-04-26 | 1999-04-26 | Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire |
FR99/05272 | 1999-04-26 | ||
US13973499P | 1999-06-18 | 1999-06-18 | |
US60/139,734 | 1999-06-18 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/983,885 Continuation US20020086004A1 (en) | 1999-04-26 | 2001-10-26 | Use of a defective recombinant adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000065043A1 true WO2000065043A1 (fr) | 2000-11-02 |
Family
ID=26234932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/001060 WO2000065043A1 (fr) | 1999-04-26 | 2000-04-21 | Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire |
Country Status (17)
Country | Link |
---|---|
US (1) | US20020086004A1 (fr) |
EP (1) | EP1173564A1 (fr) |
JP (1) | JP2002543097A (fr) |
KR (1) | KR20020001846A (fr) |
CN (1) | CN1376197A (fr) |
AU (1) | AU782833B2 (fr) |
BR (1) | BR0010034A (fr) |
CA (1) | CA2370404A1 (fr) |
CZ (1) | CZ20013813A3 (fr) |
HU (1) | HUP0200961A3 (fr) |
IL (1) | IL145834A0 (fr) |
MX (1) | MXPA01010849A (fr) |
NO (1) | NO20015223D0 (fr) |
NZ (1) | NZ515233A (fr) |
PL (1) | PL351114A1 (fr) |
SI (1) | SI20750A (fr) |
WO (1) | WO2000065043A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004533411A (ja) * | 2001-01-26 | 2004-11-04 | カイロン コーポレイション | 血管形成的に有効なfgf−2の単位用量および使用方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7223724B1 (en) * | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
NZ518077A (en) * | 2000-08-04 | 2003-11-28 | Human Genome Sciences Inc | Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease |
WO2002083704A1 (fr) * | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Facteur de croissance 2, endothelial, vasculaire |
US20050232921A1 (en) * | 2001-04-13 | 2005-10-20 | Rosen Craig A | Vascular endothelial growth factor 2 |
WO2002083849A2 (fr) * | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Facteur de croissance endothélial vasculaire 2 |
KR100697321B1 (ko) * | 2005-07-27 | 2007-03-20 | 박기랑 | VEGF-A, VEGF-B 및 VEGF-C의 안티센스cDNA를 함유하는 재조합 아데노-연관바이러스(rAAV) 및 이를 함유하는 대장암, 방광암및/또는 폐암 특이적 유전자 치료제 |
RU2558794C2 (ru) * | 2009-06-25 | 2015-08-10 | Байолидерс Корпорейшн | Адъювантная композиция, содержащая наночастицы поли-гамма-глутаминовой кислоты-хитозан |
CN105833248A (zh) * | 2016-04-27 | 2016-08-10 | 温州医科大学附属第医院 | 成纤维细胞生长因子21的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995025803A1 (fr) * | 1994-03-18 | 1995-09-28 | Rhone-Poulenc Rorer S.A. | ADENOVIRUS RECOMBINANTS CODANT POUR LE FACTEUR DE CROISSANCE DES FIBROBLASTES ACIDES (aFGF) |
WO1997030155A1 (fr) * | 1996-02-15 | 1997-08-21 | Chiron Corporation | Methode de therapie genique au moyen de fgf-5 |
WO1998020027A2 (fr) * | 1996-11-01 | 1998-05-14 | Eurogene Limited | Utilisation therapeutique d'un facteur de croissance et systeme d'administration, en particulier pour le traitement de l'hyperplasie endoveineuse |
WO1998037185A2 (fr) * | 1997-02-20 | 1998-08-27 | The Board Of Regents Of The University Of Texas System | Vecteurs pour expression genique regulee |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6423751B1 (en) * | 1998-07-14 | 2002-07-23 | The Brigham And Women's Hospital, Inc. | Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization |
-
2000
- 2000-04-21 BR BR0010034-0A patent/BR0010034A/pt not_active IP Right Cessation
- 2000-04-21 AU AU43017/00A patent/AU782833B2/en not_active Ceased
- 2000-04-21 HU HU0200961A patent/HUP0200961A3/hu unknown
- 2000-04-21 WO PCT/FR2000/001060 patent/WO2000065043A1/fr not_active Application Discontinuation
- 2000-04-21 CZ CZ20013813A patent/CZ20013813A3/cs unknown
- 2000-04-21 SI SI200020023A patent/SI20750A/sl not_active IP Right Cessation
- 2000-04-21 MX MXPA01010849A patent/MXPA01010849A/es not_active Application Discontinuation
- 2000-04-21 IL IL14583400A patent/IL145834A0/xx unknown
- 2000-04-21 JP JP2000614380A patent/JP2002543097A/ja not_active Withdrawn
- 2000-04-21 CN CN00806521A patent/CN1376197A/zh active Pending
- 2000-04-21 KR KR1020017013633A patent/KR20020001846A/ko not_active Application Discontinuation
- 2000-04-21 EP EP00922713A patent/EP1173564A1/fr not_active Withdrawn
- 2000-04-21 PL PL00351114A patent/PL351114A1/xx not_active IP Right Cessation
- 2000-04-21 CA CA002370404A patent/CA2370404A1/fr not_active Abandoned
- 2000-04-21 NZ NZ515233A patent/NZ515233A/en unknown
-
2001
- 2001-10-25 NO NO20015223A patent/NO20015223D0/no not_active Application Discontinuation
- 2001-10-26 US US09/983,885 patent/US20020086004A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995025803A1 (fr) * | 1994-03-18 | 1995-09-28 | Rhone-Poulenc Rorer S.A. | ADENOVIRUS RECOMBINANTS CODANT POUR LE FACTEUR DE CROISSANCE DES FIBROBLASTES ACIDES (aFGF) |
WO1997030155A1 (fr) * | 1996-02-15 | 1997-08-21 | Chiron Corporation | Methode de therapie genique au moyen de fgf-5 |
WO1998020027A2 (fr) * | 1996-11-01 | 1998-05-14 | Eurogene Limited | Utilisation therapeutique d'un facteur de croissance et systeme d'administration, en particulier pour le traitement de l'hyperplasie endoveineuse |
WO1998037185A2 (fr) * | 1997-02-20 | 1998-08-27 | The Board Of Regents Of The University Of Texas System | Vecteurs pour expression genique regulee |
Non-Patent Citations (1)
Title |
---|
PARTOVIAN C. ET AL.: "Adenoviral mediated VEGF overexpression reduces chronic hypoxic pulmonary hypertension in rats.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 159, no. 3 SUPPL., March 1999 (1999-03-01), pages A167, XP002127371 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004533411A (ja) * | 2001-01-26 | 2004-11-04 | カイロン コーポレイション | 血管形成的に有効なfgf−2の単位用量および使用方法 |
Also Published As
Publication number | Publication date |
---|---|
NO20015223L (no) | 2001-10-25 |
NZ515233A (en) | 2004-08-27 |
EP1173564A1 (fr) | 2002-01-23 |
HUP0200961A3 (en) | 2004-11-29 |
PL351114A1 (en) | 2003-03-24 |
CZ20013813A3 (cs) | 2002-02-13 |
HUP0200961A2 (hu) | 2002-07-29 |
JP2002543097A (ja) | 2002-12-17 |
IL145834A0 (en) | 2002-07-25 |
CN1376197A (zh) | 2002-10-23 |
AU782833B2 (en) | 2005-09-01 |
SI20750A (sl) | 2002-06-30 |
BR0010034A (pt) | 2002-01-15 |
US20020086004A1 (en) | 2002-07-04 |
AU4301700A (en) | 2000-11-10 |
KR20020001846A (ko) | 2002-01-09 |
MXPA01010849A (es) | 2002-11-07 |
CA2370404A1 (fr) | 2000-11-02 |
NO20015223D0 (no) | 2001-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2163256C (fr) | Vecteurs adenoviraux d'origine animale et utilisation en therapie genique | |
AU666142B2 (en) | Viral recombinant vectors for expression in muscle cells | |
EP0667912B1 (fr) | Vecteurs adenoviraux defectifs et utilisation en therapie genique | |
EP0752004B1 (fr) | Adenovirus recombinants codant pour le facteur neurotrophique des cellules gliales (gdnf) | |
EP0833896A1 (fr) | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant | |
JP2002502608A (ja) | 血管新生促進因子である血管内皮細胞成長因子:vegfの変異体 | |
WO1996012030A1 (fr) | Adenovirus defectifs comprenant un gene therapeutique et un gene immunoprotecteur | |
WO1996018740A1 (fr) | Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux | |
FR2707664A1 (fr) | Vecteurs viraux et utilisation en thérapie génique. | |
EP1187919B1 (fr) | Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis) | |
WO2000065043A1 (fr) | Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire | |
CA2197904A1 (fr) | Adenovirus recombinants defectifs avec un gene iva2 inactive | |
FR2731710A1 (fr) | Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique | |
FR2755699A1 (fr) | Nouvelles constructions et vecteurs pour l'expression ciblee et inductible des genes | |
FR2860004A1 (fr) | Nouveau vecteur adenoviral pour l'infection de cellules deficientes ou depourvues en recepteurs car | |
FR2792531A1 (fr) | Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire | |
WO2000028062A1 (fr) | Nouveau systeme de regulation de l'expression d'un transgene | |
CA2343922A1 (fr) | Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire | |
FR2718749A1 (fr) | Vecteurs viraux et utilisation en thérapie génique. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00806521.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2370404 Country of ref document: CA Ref document number: 2370404 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2001-3813 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017013633 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2000 614380 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/010849 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09983885 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000922713 Country of ref document: EP Ref document number: 515233 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200020023 Country of ref document: SI |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017013633 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000922713 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-3813 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017013633 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000922713 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2001-3813 Country of ref document: CZ |